US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voya Infrastructure Industrials and Materials Fund

11.71

+0.01910.16%

Post-market: 11.710.00000.00%15:40 EDT

Volume:21.90K

Turnover:256.22K

Market Cap:225.74M

PE:- -

High:11.71

Open:11.70

Low:11.69

Close:11.69

Loading ...

Overview Company News Filings

Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)

ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System

Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising

Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US

Simply Wall St.

Anteris Reports One-Year Patient Outcomes for DurAVR® THV

BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery

Realtek to Showcase Datavault AI’s Acoustic Divisions WiSA E at Convergence India Expo, Featuring Solutions Supporting India’s AI and Blockchain Initiatives

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

Press Release: Voya Equity Closed End Funds Declare Distributions

NYIAX Technology Platform Powered by Nasdaq Collaborates with Datavault AI’s Patented Information Data Exchange® through Co-Marketing and Technology Alliance

First Patient Enrolled in Merit Medical’s PREEMIE Study

Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

Datavault® AI’s WiSA Association Announces WiSA SoundSend Certification for Optoma HCPro-4400 4K UHD DLP Projector

Datavault AI to Participate at the 37th Annual Roth Conference

Press Release: Spinal Stabilization Technologies(TM) Announces Enrollment of First U.S. Patient in IDE Trial for PerQdisc(TM) Nucleus Replacement Device

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

ACCESS Newswire

MPLAB® XC Unified Compiler Licenses Deliver Streamlined Software Management

Voya Equity Closed End Funds Declare Distributions

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/IDE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IDE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","market":"US","secType":"STK","nameCN":"Voya Infrastructure Industrials and Materials Fund","latestPrice":11.7091,"timestamp":1751562000000,"preClose":11.69,"halted":0,"volume":21900,"hourTrading":{"tag":"盘后","latestPrice":11.7091,"preClose":11.7091,"latestTime":"15:40 EDT","volume":243,"amount":2812.2264,"timestamp":1751571651521},"delay":0,"floatShares":0,"shares":19279000,"eps":0,"marketStatus":"Market Closed","change":0.0191,"latestTime":"07-03 13:00:00 EDT","open":11.7,"high":11.71,"low":11.69,"amount":256224.4812,"amplitude":0.001711,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":11.69,"aum":0,"dividendRate":0.102484,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":11.7091,"preClose":11.7091,"latestTime":"15:40 EDT","volume":243,"amount":2812.2264,"timestamp":1751571651521},"volumeRatio":0.5525318665450013},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5525318665450013,"shares":19279000,"dividePrice":1.2,"high":11.71,"amplitude":0.001711,"preClose":11.69,"low":11.69,"week52Low":8.75,"pbRate":"--","week52High":11.766,"institutionHeld":0,"latestPrice":11.7091,"eps":0,"divideRate":0.102484,"volume":21900,"delay":0,"ttmEps":0,"open":11.7,"prevYearClose":10.15,"prevWeekClose":11.69,"prevMonthClose":11.69,"prevQuarterClose":11.69,"fiveDayClose":11.65,"twentyDayClose":11.36,"sixtyDayClose":9.1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524970260","title":"Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2524970260","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524970260?lang=en_us&edition=fundamental","pubTime":"2025-04-01 05:00","pubTimestamp":1743454800,"startTime":"0","endTime":"0","summary":"Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052830/0/en/Glucotrack-Reports-Full-Year-2024-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","GCTK","IDE"],"gpt_icon":0},{"id":"2522306934","title":"Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms","url":"https://stock-news.laohu8.com/highlight/detail?id=2522306934","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522306934?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:00","pubTimestamp":1743080400,"startTime":"0","endTime":"0","summary":"Abbott's Volt PFA System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation. Pulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to targeting and treating tissue in the heart. Abbott's Volt PFA System is designed to overcome limitations of existing PFA systems, providing improved workflows and a clearer indication of contact between the Volt PFA catheter and targeted tissue. ABBOTT PARK, Ill., March 27, 2025 /PRNewswire/ -- Abbott  today announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation . With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott's PFA clinical studies. The company will further expand use of Volt in EU markets throughout the second half of the year.Volt PFA Syste","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbott-receives-ce-mark-volt-130000876.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbott-receives-ce-mark-volt-130000876.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1691799644.USD","BK4213","PVI","BK4504","BK4109","SG9999002232.USD","LU0868494617.USD","BK4082","BK4588","LU1721429402.USD","BK4533","CE","SG9999002224.SGD","LU1989763427.SGD","LU1989763690.USD","LU2237957902.USD","IE0002141913.USD","LU0266013472.USD","BK4585","SGXZ23171101.USD","LU1914381329.SGD","IDE","LU0170899867.USD","LU2133065610.SGD","IE00BJJMRZ35.SGD","SG9999004303.SGD","LU0122379950.USD","LU1023059063.AUD","LU2112291526.USD","IE0009355771.USD","IE00B4R5TH58.HKD","BK4581","LU2089984988.USD","LU0234572021.USD","IE00B2B36J28.USD","LU1061106388.HKD","IE00BJT1NW94.SGD","EP","BK4566","ABT","BK4592","LU2237957811.SGD","LU2468319806.SGD","BK4568","IE00BFTCPJ56.SGD","LU1057294990.SGD","LU1721429741.USD"],"gpt_icon":0},{"id":"2522074303","title":"Merit Medical Releases 12-Month Efficacy Results of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522074303","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522074303?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:25","pubTimestamp":1742909100,"startTime":"0","endTime":"0","summary":"At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target les","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048850/8028/en/Merit-Medical-Releases-12-Month-Efficacy-Results-of-the-WRAPSODY-Cell-Impermeable-Endoprosthesis-CIE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0566484027.USD","BK4539","BK4588","CE","WAVE","IDE","BK4109","MMSI","LU1559883803.SGD","BK4198","BK4133"],"gpt_icon":0},{"id":"2522009664","title":"ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System","url":"https://stock-news.laohu8.com/highlight/detail?id=2522009664","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522009664?lang=en_us&edition=fundamental","pubTime":"2025-03-25 21:16","pubTimestamp":1742908560,"startTime":"0","endTime":"0","summary":"Abbott ABT has received the FDA’s investigational device exemption  for its Coronary Intravascular Lithotripsy  system to evaluate the treatment of severe calcification in coronary arteries prior to stenting. The TECTONIC Coronary Artery Disease  Intravascular Lithotripsy  clinical trial will enroll up to 335 people in 47 sites in the United States.The company’s investigational Coronary IVL technology builds upon its existing vascular portfolio, part of the Medical Devices segment, and is designed to address the challenges of currently available IVL systems.Per a Research report, the global CAD market was valued at $22.07 billion in 2024 and is set to witness a compound annual rate of 8.9% through 2031. The rising CAD prevalence around the world fuels the market’s growth, along with higher funding for research and development of therapies and an increase in comorbid conditions, including atherosclerosis and hypertension.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abt-stock-gain-fda-ide-131600566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","ABT","LU1718418525.SGD","IE0009355771.USD","LU1791710582.SGD","LU2506952097.USD","LU2087625088.SGD","IE0002141913.USD","LU2362541513.USD","BK4175","LU2506951958.HKD","IDE","LU1571399168.USD","SG9999002232.USD","CAH","LU0211327993.USD","LU0266013472.USD","BSX","LU1291159041.SGD","BK4533","SG9999001440.SGD","LU1914381329.SGD","LU0823417737.USD","LU0251132253.USD","LU2237957902.USD","LU1983299246.USD","LU0310800965.SGD","LU1989764748.USD","LU2468319806.SGD","LU0048584097.USD","BK4588","LU0114720955.EUR","LU0310799852.SGD","LU0868494617.USD","LU2491050154.USD","LU0154236417.USD","BK4568","LU1791710400.SGD","LU1267930490.SGD","LU0238689110.USD","LU2242649171.HKD","LU0072461881.USD","LU0170899867.USD","LU0162691827.USD","IE00BFTCPJ56.SGD","BK4196","LU0011850046.USD","LU0187121727.USD"],"gpt_icon":1},{"id":"2522002742","title":"Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising","url":"https://stock-news.laohu8.com/highlight/detail?id=2522002742","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522002742?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:57","pubTimestamp":1742903820,"startTime":"0","endTime":"0","summary":"Licensing Deal Strengthens Focus on Information Data Exchange While Introducing a Privacy-First Advertising Category. BEAVERTON, Ore., March 25, 2025----Datavault AI Inc. , a leader in AI-driven data valuation and monetization, today announced a strategic licensing agreement with NYIAX, the Nasdaq-powered trading platform. This agreement integrates Datavault AI’s patented ADIO technology into NYIAX’s cutting-edge advertising exchange, creating one of the world’s first fully functional ultrasonic advertising platforms. Technical integration is expected to be completed in Q2 2025, with combined product offerings available for customer deployments in 2H 2025.\"Authenticated scalability and direct consumer engagement are no longer optional for brands seeking competitive differentiation,\" said Joseph Stonbely II, Founder & Executive Producer of Mission: IGNITION  \"We’ve long considered the NYIAX platform our most essential front-line resource for delivering meaningful, value-engineered brand","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datavault-ai-licenses-patented-adio-115700241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["USAW.SI","ML","PSQ","NVIW.SI","USJW.SI","QLD","SQQQ","BK4166","MNQmain","IDE","DVLT","TQQQ","QID",".IXIC","BK4141","NQmain","TSYW.SI"],"gpt_icon":1},{"id":"2522608342","title":"Abbott Laboratories (NYSE:ABT) Receives FDA Approval For Coronary IVL System Trial In US","url":"https://stock-news.laohu8.com/highlight/detail?id=2522608342","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522608342?lang=en_us&edition=fundamental","pubTime":"2025-03-25 01:20","pubTimestamp":1742836822,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (NYSE:ABT) has caught investor attention with the FDA’s approval of an Investigational Device Exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System, a significant development within the realm of coronary artery disease treatment. This announcement comes in conjunction with the company's recent robust Q4 2024 earnings results, reporting net income and diluted EPS growth. Additionally, Abbott declared its 405th consecutive quarterly dividend and outlined...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-nyseabt-receives-fda-approval-for-corona","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2089984988.USD","LU2468319806.SGD","BK4585","BK4566","LU1691799644.USD","LU1914381329.SGD","LU1989763427.SGD","BK4504","LU2237957902.USD","LU1721429402.USD","IE00B2B36J28.USD","LU2112291526.USD","LU1023059063.AUD","LU1721429741.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","LU0234572021.USD","IE0009355771.USD","LU0170899867.USD","IE00BFTCPJ56.SGD","LU0266013472.USD","LU1989763690.USD","LU1061106388.HKD","SG9999004303.SGD","BK4592","LU0868494617.USD","LU2237957811.SGD","BK4082","IE00B4R5TH58.HKD","ABT","SG9999002232.USD","BK4581","BK4568","LU0122379950.USD","LU2133065610.SGD","SG9999002224.SGD","BK4533","IDE","BK4588","IE00BJT1NW94.SGD","NYSE","SGXZ23171101.USD","LU1057294990.SGD"],"gpt_icon":0},{"id":"2521400898","title":"Anteris Reports One-Year Patient Outcomes for DurAVR® THV","url":"https://stock-news.laohu8.com/highlight/detail?id=2521400898","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521400898?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:30","pubTimestamp":1742556600,"startTime":"0","endTime":"0","summary":"New class, biomimetic TAVR demonstrates sustained hemodynamic performance to one-yearMINNEAPOLIS and BRISBANE, Australia, March  21, 2025  (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/21/3047015/0/en/Anteris-Reports-One-Year-Patient-Outcomes-for-DurAVR-THV.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","IDE","AVR"],"gpt_icon":0},{"id":"2520443767","title":"BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=2520443767","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520443767?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:50","pubTimestamp":1742467800,"startTime":"0","endTime":"0","summary":"FRANKLIN LAKES, N.J., March 20, 2025 /PRNewswire/ --BD  , a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption  clinical trial intended to advance BD's efforts to achieve Premarket Approval  from the U.S. Food and Drug Administration  for the use of GalaFLEX LITE Scaffold in decreasing capsular contracture  recurrence during breast revision surgery.\"This milestone marks a significant advancement in our efforts to achieve FDA Premarket Approval for our first breast indication for GalaFLEX LITE Scaffold and reinforces the company's commitment to improving patient outcomes through innovative technologies that reduce surgical complications,\" said Rian Seger,worldwide president of the BD Surgery business. \"Our team has worked closely with the FDA to help address a critical medical complication arising from implant-based breast surgery, and the first patient treated brings us closer to delivering a much-needed solution.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/bd-announces-milestone-clinical-trial-105000559.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bd-announces-milestone-clinical-trial-105000559.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0205193047.USD","LU0289739343.SGD","LU2211817866.USD","LU0985320562.USD","BK4098","LU0433182093.SGD","LU0205194284.USD","BK4588","LU1894683348.USD","LU0878866978.SGD","LU1059921491.USD","ADM","LU1489326972.SGD","BK4597","BK4585","LU0985489474.SGD","BK4504","LU0068578508.USD","IE00BFXG1179.USD","BK4082","LU0240877869.USD","LU1150488135.SGD","LU0511384066.AUD","LU0385154629.USD","LU1854103824.USD","LITE","BDX","LU0012050646.USD","BK4020","CC","LU0106261612.USD","LU0266013472.USD","LU1894683264.USD","LU1150488218.USD","LU0240878834.USD","LU0289961442.SGD","IDE","LU1854104046.USD","BK4189","LU1571399168.USD","LU0471298777.SGD"],"gpt_icon":0},{"id":"2520802741","title":"Realtek to Showcase Datavault AI’s Acoustic Divisions WiSA E at Convergence India Expo, Featuring Solutions Supporting India’s AI and Blockchain Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2520802741","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520802741?lang=en_us&edition=fundamental","pubTime":"2025-03-19 21:15","pubTimestamp":1742390100,"startTime":"0","endTime":"0","summary":"Realtek and WiSA E to Demonstrate a SDK for the Set-Top Box Market Enabling Turnkey Multichannel Audio Powered by WiSA E and Realtek. This collaboration between Datavault AI and Realtek comes at a time in India’s digital transformation that aligns with the government’s initiatives in AI, blockchain, and secure data management. The addition of Data Vault and ADIO, patented AI and blockchain solutions, positions Datavault AI for enterprise contracting and seamless integration into India’s corporate, government, and transportation sectors. These advanced technologies offer innovative solutions in AI-driven data monetization, blockchain-based security, and intelligent engagement systems, making them ideal for large-scale infrastructure projects, telecom providers, smart cities, and financial institutions.Prime Minister Modi recently stated, \"Artificial intelligence, machine learning, Internet of Things, blockchain, and big data hold potential to take India to new heights of development and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/realtek-showcase-datavault-ai-acoustic-131500438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4141","IDE","DVLT","BK4166","CAGR","BK4159","ML"],"gpt_icon":0},{"id":"2520683236","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2520683236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520683236?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:30","pubTimestamp":1742243400,"startTime":"0","endTime":"0","summary":"VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION. Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in February 2025. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the March distribution. It is not determinative of the tax character of the Funds' distributions for the 2025 calendar year. Shareholders should note that the Funds' total regular distribution amount","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU1878469433.USD","FUND","ARKG","BK4184","NAV","IDE","VOYA","LU0211331839.USD","IGA"],"gpt_icon":0},{"id":"2520129688","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2520129688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520129688?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:15","pubTimestamp":1742242500,"startTime":"0","endTime":"0","summary":"Voya Investment Management, the asset management business of Voya Financial, Inc. , announced today the distributions on the common shares of five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund , Voya Infrastructure, Industrials and Materials Fund , Voya Asia Pacific High Dividend Equity Income Fund , and Voya Emerging Markets High Dividend Equity Fund .With respect to each Fund, the distribution will be paid on April 15, 2025, to shareholders of record on April 1, 2025. The ex-dividend date is April 1, 2025. The distribution per share for each Fund is as follows:. The following table sets forth an estimate of the sources of each Fund's February distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Estimated Sources                             Fiscal YTD                      Estima","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4215","LU0061475181.USD","LU0211331839.USD","BK4588","VOYA","IGD","NAV","BK4184","BK4022","BK4232","BK4585","IAE","IDE","IGA","LU1878469433.USD","EQR","IHD"],"gpt_icon":0},{"id":"2520528488","title":"NYIAX Technology Platform Powered by Nasdaq Collaborates with Datavault AI’s Patented Information Data Exchange® through Co-Marketing and Technology Alliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2520528488","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520528488?lang=en_us&edition=fundamental","pubTime":"2025-03-17 20:07","pubTimestamp":1742213220,"startTime":"0","endTime":"0","summary":"Unlocking New Revenue Streams: Transforming Real-World Assets and Data into Financial Opportunities. BEAVERTON, Ore., March 17, 2025----Datavault AI Inc. , a leader in AI-driven data experience, valuation, and monetization, today announced a multi-year commercial and intellectual property  alliance with NYIAX, a pioneer in transparent trading technology built on the Nasdaq financial framework. This partnership will integrate Datavault AI’s patented Information Data Exchange  and award-winning Data Vault platform with NYIAX’s cutting-edge blockchain exchange technology. The collaboration leverages NYIAX's capabilities, enabling businesses to scale, list, price, and trade data and digital assets efficiently, creating new revenue opportunities. With the increasing recognition of data as a strategic financial asset, this partnership provides businesses with the infrastructure to monetize data in a secure and scalable environment, bridging the gap between data valuation and liquidity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nyiax-technology-platform-powered-nasdaq-120700432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","IE00B3QW5Z07.USD","LU1487256676.USD","PSQ","IE00BKPKM429.USD","LU1481600234.SGD","BK4588","TQQQ","MNQmain","IDE","BK4112","DVLT","NDAQ","LU2463526074.USD","IE00BGHQF748.EUR","BK4136","LU2210150020.SGD","IP","QID","TSYW.SI","BK4134","BK4585","NVIW.SI","III","USAW.SI","BK4141","LU2095319765.USD",".IXIC","QLD","SQQQ","USJW.SI","LU1481599808.USD","LU2210149790.SGD","NQmain"],"gpt_icon":1},{"id":"2518224585","title":"First Patient Enrolled in Merit Medical’s PREEMIE Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518224585","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518224585?lang=en_us&edition=fundamental","pubTime":"2025-03-10 21:25","pubTimestamp":1741613100,"startTime":"0","endTime":"0","summary":"Multicenter, prospective study designed to evaluate safety and efficacy of Bloom Micro Occluder System for treatment of patent ductus arteriosus in premature infantsSOUTH JORDAN, Utah, March  10, 2025","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/10/3039830/8028/en/First-Patient-Enrolled-in-Merit-Medical-s-PREEMIE-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","LU0566484027.USD","IDE","MMSI","BK4198"],"gpt_icon":0},{"id":"2518228430","title":"Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228430","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518228430?lang=en_us&edition=fundamental","pubTime":"2025-03-10 20:01","pubTimestamp":1741608060,"startTime":"0","endTime":"0","summary":"Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier Beyond Virology and Oncology. Results Support Further Evaluation of the Hemopurifieras Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys. Aethlon Medical's Hemopurifieris a therapeutic blood filtration system designed to bind and remove harmful extracellular vesicles and life-threatening viruses from blood and other biological fluids. Its capabilities have potential applications in oncology and infectious diseases, and organ transplantation.\"While the company's funding and focus are dedicated to the Australian and India Oncology trials, the data generated from this pre-clinical study demonstrates that extracellular vesicle removal as a therapeutic target for the Hemopurifier extends beyond virology and oncology. We believe there exists a \"pipeline within a device\",\" added James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. Ho","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/aethlon-medical-publishes-preclinical-data-120100694.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aethlon-medical-publishes-preclinical-data-120100694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","IDE","AEMD","BK4583","BK4082"],"gpt_icon":0},{"id":"2517659911","title":"Datavault® AI’s WiSA Association Announces WiSA SoundSend Certification for Optoma HCPro-4400 4K UHD DLP Projector","url":"https://stock-news.laohu8.com/highlight/detail?id=2517659911","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517659911?lang=en_us&edition=fundamental","pubTime":"2025-03-06 22:05","pubTimestamp":1741269900,"startTime":"0","endTime":"0","summary":"Certification ensures compatibility with the upcoming SoundSend E for seamless wireless audio experiences. BEAVERTON, Ore., March 06, 2025----Datavault AI , formerly known as WiSA Technologies, Inc., is pleased to announce that Optoma’s HCPro-4400 4K UHD DLP laser projector has received WiSA SoundSend Certification. This certification ensures seamless compatibility with the award-winning WiSA SoundSend wireless audio transmitter, as well as the upcoming SoundSend E product, allowing users to experience immersive, high-fidelity audio effortlessly.\"We are thrilled to have our HCPro-4400 4K UHD DLP projector achieve WiSA SoundSend Certification,\" said Brian Soto, Director of Product Management at Optoma. \"This milestone underscores our commitment to providing our customers with cutting-edge technology that delivers exceptional audio and visual experiences.\". Launched in November 2020, the WiSA SoundSend was the Association's first branded product and the first WiSA-certified wireless audi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datavault-ai-wisa-association-announces-140500264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ML","BK4141","DVLT","IDE","BK4166"],"gpt_icon":0},{"id":"2516674279","title":"Datavault AI to Participate at the 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516674279","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516674279?lang=en_us&edition=fundamental","pubTime":"2025-03-04 22:05","pubTimestamp":1741097100,"startTime":"0","endTime":"0","summary":"- Will Discuss Web 3.0 Data Monetization Strategy and Forthcoming CSI Acquisition -. Datavault AI1,  is leading the way in AI experience, valuation, and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA, ADIO and Sumerian patented technologies and industry first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/datavault-ai-participate-37th-annual-140500532.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IDE","DVLT","ML","BK4141","BK4166"],"gpt_icon":0},{"id":"2516654979","title":"Press Release: Spinal Stabilization Technologies(TM) Announces Enrollment of First U.S. Patient in IDE Trial for PerQdisc(TM) Nucleus Replacement Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2516654979","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516654979?lang=en_us&edition=fundamental","pubTime":"2025-03-04 02:17","pubTimestamp":1741025820,"startTime":"0","endTime":"0","summary":"Spinal Stabilization Technologies Announces Enrollment of First U.S. Patient in IDE Trial for PerQdisc Nucleus Replacement Device. Dr. Pierce Nunley completes the first U.S. PerQdisc Surgery Spine Surgeon Dr. Frank Phillips Joins SST Board of Directors. Spine Surgeon Frank Phillips, MD Joins Board of Spinal Stabilization Technologies. SST is also pleased to announce the appointment of Dr. Frank Phillips to its Board of Directors. Dr. Phillips is one of the world's leading spine surgeons and has been the president of global spine societies. He has pioneered minimally invasive procedures, has over 200 spine-related publications and trained numerous spine surgeons. He holds patents in the spine space, has founded spine companies and served on the board of directors of public and private companies. \"His expertise and leadership in the field of spinal surgery will be instrumental in guiding SST's strategic direction and clinical adoption,\" commented Mark Novotny, CEO of SST.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","IDE","BK4604","03160","SST","BK4099","TM","BK4588","BK4555","BK4551","BK4585","BK4077","BK4546","DDD","BK4161"],"gpt_icon":0},{"id":"2514324902","title":"enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2514324902","media":"ACCESS Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514324902?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"Cash Burn of $5.2 million in Q4 remains in line with projected $4-5 million quarterly range. Cash and investments on hand are sufficient to fund operations beyond the anticipated regulatory approval of VenoValve and the initiation of the enVVe pivotal trial. PMA application for the VenoValve submitted, with FDA decision expected in the second half of 2025. On track for enVVe IDE application submission by mid-2025, pending GLP study results. IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation  , a company setting new standards of care for the treatment of venous disease, today provided a corporate update and reported financial results for the fourth quarter and year-end of 2024.The Company reported net losses of $21.8 million and $23.5 million for the years ended December 31, 2024 and 2023, respectively, representing a decrease in net loss of $1.7 million or 7%, resulting from a decrease in operating expenses of $1.5 million, and an increase in other income of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/envveno-medical-reports-fourth-quarter-130000940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVI","BK4082","BK4097","PRGS","LU2065732104.USD","BK4138","NVNO","IDE"],"gpt_icon":0},{"id":"2513043728","title":"MPLAB® XC Unified Compiler Licenses Deliver Streamlined Software Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2513043728","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513043728?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:07","pubTimestamp":1740398820,"startTime":"0","endTime":"0","summary":"Unified solution allows Microchip Technology to provide flexible and cost-effective licensing options for its line of compilers. CHANDLER, Ariz., Feb. 24, 2025  -- Offering an efficient way to manage multiple licenses, Microchip Technology  has launched MPLAB XC Unified Compiler Licensesfor its MPLAB XC8, XC16, XC-DSC and XC32 C compilers. This unified approach addresses the financial strain and administrative burden of purchasing and managing separate software access models for each compiler. Microchip’s solution consolidates the necessary licenses to reduce overhead and provide greater flexibility, scalability and ease of use.The unified system is designed to accommodate evolving development needs, offering multiple tiers to suit growing teams. The Workstation License can be installed and executed on up to three host machines for use by a single engineer. The Network Server License allows installation on a server, accessible by any machine on the network, one at a time. The Subscript","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mplab-xc-unified-compiler-licenses-120700904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087625088.SGD","BK4604","BK4605","XC","LU0353189763.USD","BK4588","BK4512","LU0353189680.USD","LU1720051017.SGD","LU1720051108.HKD","LU1983260115.SGD","BK4141","LU1548497426.USD","LU0348723411.USD","IDE","IPE","BK4585","LU0342679015.USD","LU2357305700.SGD","BK4529","MCHP"],"gpt_icon":0},{"id":"2512903031","title":"Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2512903031","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512903031?lang=en_us&edition=fundamental","pubTime":"2025-02-19 05:30","pubTimestamp":1739914200,"startTime":"0","endTime":"0","summary":"With respect to each Fund, the distribution will be paid on March 17, 2025, to shareholders of record on March 3, 2025. The ex-dividend date is March 3, 2025. The distribution per share for each Fund is as follows:. Voya Global Equity Dividend and Premium Opportunity Fund . Voya Asia Pacific High Dividend Equity Income Fund . The following table sets forth an estimate of the sources of each Fund’s January distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Set forth in the tables below is information relating to each Fund’s performance based on its net asset value  for certain periods.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voya-equity-closed-end-funds-213000770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IGD","LU1878469433.USD","EQR","IDE","IHD","IGA","NAV","IAE","LU0211331839.USD","BK4215","VOYA","BK4588","BK4585","BK4184","LU0061475181.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDE\",params:#limit:5,,,undefined,":[{"date":"2025-07-01","symbol":"IDE","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-07-01","defaultRemindTime":1751376600000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-15","payableDate":"2025-07-01","currency":"USD","dateTimestamp":1751342400000,"payDate":"2025-07-15"},{"date":"2025-06-02","symbol":"IDE","amount":0.1,"announcedDate":"2025-05-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-02","defaultRemindTime":1748871000000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-16","payableDate":"2025-06-02","currency":"USD","dateTimestamp":1748836800000,"payDate":"2025-06-16"},{"date":"2025-05-01","symbol":"IDE","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-01","defaultRemindTime":1746106200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-15","payableDate":"2025-05-01","currency":"USD","dateTimestamp":1746072000000,"payDate":"2025-05-15"},{"date":"2025-04-01","symbol":"IDE","amount":0.1,"announcedDate":"2025-03-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-01","defaultRemindTime":1743514200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-15","payableDate":"2025-04-01","currency":"USD","dateTimestamp":1743480000000,"payDate":"2025-04-15"},{"date":"2025-03-03","symbol":"IDE","amount":0.1,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-17","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDE\",market:\"US\",,,undefined,":[{"executeDate":"2015-10-01","recordDate":"2015-10-05","paymentDate":"2015-10-15","value":0.365,"currency":"USD"},{"executeDate":"2015-12-29","recordDate":"2015-12-31","paymentDate":"2016-01-15","value":0.365,"currency":"USD"},{"executeDate":"2016-04-01","recordDate":"2016-04-05","paymentDate":"2016-04-15","value":0.365,"currency":"USD"},{"executeDate":"2016-07-01","recordDate":"2016-07-06","paymentDate":"2016-07-15","value":0.365,"currency":"USD"},{"executeDate":"2016-10-03","recordDate":"2016-10-05","paymentDate":"2016-10-17","value":0.365,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDE\",market:\"US\",delay:false,,,undefined,":{}}}